Revelation Biosciences Inc (REVB)

Revelation Biosciences Inc (REVB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3.3M; returns 1 day +3.0%, 1 week +681.9%, 1 year -21.7%.

Revelation Biosciences Inc. (REVB) is a clinical-stage life science company focused on rebalancing inflammation to optimize health. Their primary therapeutic candidate is Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a toll-like receptor 4 (TLR4) agonist.

Groups REVB belongs to

• Healthcare
• Biotechnology
• Recent Reverse Splits
• Clinical Stage Biotech
• Life Sciences
• Biopharmaceutical
• Clinical Stage
• Immunotherapy
• Preclinical Development
• Unmet Medical Needs
• Nephrology

REVB financial model: income statement, cash flow and balance sheet